February 27, 2007, Outcome Capital announced the completion of a $6,500,000 Series A Convertible Preferred funding round for SPADAC, the premier provider of innovative predictive and geointelligence analysis solutions, by Pequot Ventures, the direct private equity investment arm of Pequot Capital Management. Outcome Capital acted as financial advisor to SPADAC on this transaction.
Mark Dumas Chairman and CEO of SPADAC said, “As we enter a vital growth period for the company, this new relationship with Pequot Ventures will allow us to accelerate our strategic plans. We will expand our research and development activities in order to provide even broader predictive analytics to government agencies, while enhancing our efforts in selected commercial verticals. We plan to augment sales and marketing activities to provide new government clients the same advanced analysis solutions that existing customers already benefit from.
Dumas remarked that “Outcome Capital acted as our key trusted advisor in our fundraising at each step, from preparation to execution. Their senior banking team assisted management in refining our focus and financing objectives in order to identify and approach potential investors in an efficient and targeted manner. Outcome Capital’s unique in-depth market knowledge of the software and defense intelligence sectors in conjunction with their growth stage financing experience was instrumental in strategically positioning our company for fundraising success.”
Gerald A. Poch, Senior Managing Director for Pequot Ventures noted that “In its short history, SPADAC has demonstrated world-class domain expertise in combining deep geospatial knowledge with the company’s proprietary predictive analytics software engine to provide meaningful solutions for an impressive list of government agency customers,” He added that “Under Mark’s leadership, the company has assembled an impressive group of technology developers and applied sector analysts. SPADAC has a substantial number of security-cleared professionals who are engaged in solving complex problems for various government agencies. We believe SPADAC can provide compelling solutions in a cost-effective manner to a number of commercial verticals.”
SPADAC is the premier provider of relevant and actionable information to the owners to the world’s most critical decisions. Customers rely on SPADAC’s predictive and geointelligence analysis software products and services to make better decisions faster, leveraging patented technologies, visualization services and domain expertise. SPADAC’s analytical and software product solutions range from risk assessment and resource allocation to opportunity identification and discovery. With unwavering commitment, SPADAC provides its clients – including defense, intelligence, homeland security and business.The Power to Know Where®.
About Pequot Ventures
Pequot Ventures is the direct venture investment arm of Pequot Capital Management, Inc. focused on investing in today’s most dynamic startup and growth stage companies in the technology, telecommunications, and the defense sectors. Pequot Ventures creates value by bringing energy and substantial sector expertise to its portfolio companies through the collective intellectual capital, deep operating experience, and extensive network of its investment team. The firm leverages its unique multi-billion dollar presence across both public and private equity markets to help build competitive, sustainable businesses in fast changing environments throughout their lifecycle. Pequot Ventures accomplishes this goal in close partnership with the founders and management team of its portfolio companies.
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]Read More
Outcome Capital Life Science Market Pulse July 2022 Click to view our LifeSciences Pulse NewsletterDownload